Investigating how the loss of ARID1A and estrogen signaling affects endometrial cancer
Official title: The combined role of ARID1A loss and estrogen signaling in endometrial cancer
Funded at University of Utah · NIH-11047692 · Data updated 2026-11-12
This study is looking at how changes in a specific gene called ARID1A and the hormone estrogen affect the growth of endometrial cancer, with the goal of finding new ways to treat this common type of cancer in women.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | March 4, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $422,270 |
| NIH project number | 5R01CA289731-02 |
| Project ID | NIH-11047692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with endometrial cancer, particularly those with endometrioid tumors that may have ARID1A mutations.
✕Less likely to help
Patients with non-endometrial cancers or those without ARID1A mutations may not benefit from this research.
What this research studies
This research focuses on understanding the relationship between the loss of the ARID1A gene and estrogen signaling in endometrial cancer, which is the most common gynecological cancer in the U.S. The study will utilize advanced 3D cell culture techniques and animal models to explore how these factors contribute to cancer progression. By examining the interactions between ARID1A mutations and estrogen receptor activity, the research aims to identify potential vulnerabilities in cancer cells that could be targeted for treatment.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating endometrial cancer by targeting specific vulnerabilities related to ARID1A loss and estrogen signaling.
How similar studies have gone: Previous research has shown promising results in understanding the role of estrogen signaling in endometrial cancer, but the specific focus on ARID1A loss in this context is relatively novel.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Gertz, Jason — University of Utah
- Study coordinator: Gertz, Jason
Related research
Other NIH-funded projects on the same topics.
-
Prognostic tools to guide adjuvant therapy for Black women after hysterectomy for endometrial cancer
A new project aims to create and validate easy-to-use tools that help doctors tailor post-surgery treatment for Black women with endometrial cancer.
-
Understanding why guideline-concordant endometrial cancer treatment varies in high-risk groups
This project looks at why some patients with endometrial cancer don’t receive care that follows national guidelines, aiming to find ways to ensure more patients get the best-supported treatments.
-
Targeting hormone resistance to prevent endometrial cancer
Aims to boost progesterone’s cancer-preventing effect in the lining of the uterus to stop cancer from developing in people at risk, especially those who are obese or young.
-
Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
A cancer treatment study is testing whether blocking AXL with batiraxcept together with standard chemotherapy can help people with certain aggressive uterine cancers respond better.
-
Targeting HSPA Proteins to Help Women with Advanced or Recurrent Endometrial Cancer
Aims to test a drug called SHetA2 that may slow or stop growth of advanced endometrial cancer by targeting cancer-friendlier proteins, with a focus on reducing treatment toxicity.
-
Endometrial Cancer SPORE: New strategies to prevent and treat endometrial cancer
A multi-institution program is testing new ways to prevent and treat endometrial cancer in people, with three linked projects and multiple cores to support translational research.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.